JP2020535124A5 - - Google Patents

Download PDF

Info

Publication number
JP2020535124A5
JP2020535124A5 JP2020515000A JP2020515000A JP2020535124A5 JP 2020535124 A5 JP2020535124 A5 JP 2020535124A5 JP 2020515000 A JP2020515000 A JP 2020515000A JP 2020515000 A JP2020515000 A JP 2020515000A JP 2020535124 A5 JP2020535124 A5 JP 2020535124A5
Authority
JP
Japan
Prior art keywords
alkyl
cancer
heteroaryl
aryl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020515000A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020535124A (ja
JP7402792B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/052797 external-priority patent/WO2019067503A1/en
Publication of JP2020535124A publication Critical patent/JP2020535124A/ja
Priority to JP2023142246A priority Critical patent/JP2023164918A/ja
Publication of JP2020535124A5 publication Critical patent/JP2020535124A5/ja
Application granted granted Critical
Publication of JP7402792B2 publication Critical patent/JP7402792B2/ja
Priority to JP2025235397A priority patent/JP2026031721A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020515000A 2017-09-26 2018-09-26 多発性骨髄腫を治療するための新規なusp7阻害剤 Active JP7402792B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023142246A JP2023164918A (ja) 2017-09-26 2023-09-01 多発性骨髄腫を治療するための新規なusp7阻害剤
JP2025235397A JP2026031721A (ja) 2017-09-26 2025-12-05 多発性骨髄腫を治療するための新規なusp7阻害剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762563375P 2017-09-26 2017-09-26
US62/563,375 2017-09-26
PCT/US2018/052797 WO2019067503A1 (en) 2017-09-26 2018-09-26 NEW USP7 INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023142246A Division JP2023164918A (ja) 2017-09-26 2023-09-01 多発性骨髄腫を治療するための新規なusp7阻害剤

Publications (3)

Publication Number Publication Date
JP2020535124A JP2020535124A (ja) 2020-12-03
JP2020535124A5 true JP2020535124A5 (enExample) 2023-09-12
JP7402792B2 JP7402792B2 (ja) 2023-12-21

Family

ID=65903565

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020515000A Active JP7402792B2 (ja) 2017-09-26 2018-09-26 多発性骨髄腫を治療するための新規なusp7阻害剤
JP2023142246A Pending JP2023164918A (ja) 2017-09-26 2023-09-01 多発性骨髄腫を治療するための新規なusp7阻害剤
JP2025235397A Pending JP2026031721A (ja) 2017-09-26 2025-12-05 多発性骨髄腫を治療するための新規なusp7阻害剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023142246A Pending JP2023164918A (ja) 2017-09-26 2023-09-01 多発性骨髄腫を治療するための新規なusp7阻害剤
JP2025235397A Pending JP2026031721A (ja) 2017-09-26 2025-12-05 多発性骨髄腫を治療するための新規なusp7阻害剤

Country Status (6)

Country Link
US (2) US11465983B2 (enExample)
EP (1) EP3687537A4 (enExample)
JP (3) JP7402792B2 (enExample)
AU (1) AU2018342089B2 (enExample)
CA (1) CA3072353A1 (enExample)
WO (1) WO2019067503A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11465983B2 (en) 2017-09-26 2022-10-11 Dana-Farber Cancer Institute, Inc. USP7 inhibitors for treating multiple myeloma
JP7508449B2 (ja) * 2018-10-22 2024-07-01 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド Usp7の阻害
BR112021010645A2 (pt) * 2018-12-06 2021-08-17 Almac Discovery Limited composto, 1-(((s)-7-((r)-3-ciclohexil-2-metilpropanoil)-10-hidroxi-7-azaspiro[4.5]decan-10-il)metil)-4-fenil-5-(piperazina-1-carbonila)piridin-2(1h)-ona, composição farmacêutica, métodos para tratamento de obesidade, de resistência à insulina, de diabetes tipo ii, de atrofia muscular, de câncer e para reduzir perda de massa muscular, e, inibidor de usp19
WO2020227365A1 (en) * 2019-05-06 2020-11-12 Integral Early Discovery, Inc. Inhibiting usp19
CN115427076B (zh) 2020-02-28 2025-01-03 免疫学有限公司 用于治疗冠状病毒感染的人去泛素化酶抑制剂
CN112047933B (zh) * 2020-10-15 2022-06-14 郑州大学 喹唑啉酮类usp7抑制剂及其制备方法和应用
GB202104097D0 (en) * 2021-03-24 2021-05-05 Almac Discovery Ltd Pharmaceutical compounds
WO2023003973A1 (en) * 2021-07-20 2023-01-26 Dana-Farber Cancer Institute, Inc. Inhibitors targeting ubiquitin specific protease 7 (usp7)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3344099A (en) * 1998-04-17 1999-11-08 Kyowa Hakko Kogyo Co. Ltd. Analgetic agent
AU2003218737B2 (en) 2002-03-13 2008-04-10 Janssen Pharmaceutica N.V. Inhibitors of histone deacetylase
WO2007147217A1 (en) * 2006-06-22 2007-12-27 Prana Biotechnology Limited Method of treatment of glioma brain tumour
EP2565186A1 (en) * 2011-09-02 2013-03-06 Hybrigenics S.A. Selective and reversible inhibitors of ubiquitin specific protease 7
HK1248220A1 (zh) 2015-02-05 2018-10-12 Forma Therapeutics, Inc. 喹唑啉酮和偶氮喹唑啉作为泛特丁胺蛋白酶7抑制剂
HK1248221A1 (zh) 2015-02-05 2018-10-12 Forma Therapeutics, Inc. 异噻唑啉酮类,吡唑并嘧啶酮类和吡咯并嘧啶酮作为泛蛋白特异性蛋白酶7抑制剂
HK1248222A1 (zh) * 2015-02-05 2018-10-12 Forma Therapeutics, Inc. 噻吩并嘧啶酮作为泛素特异性蛋白酶7抑制剂
GB201612938D0 (en) * 2016-07-26 2016-09-07 Almac Discovery Ltd Pharmaceutical compounds
GB201617758D0 (en) * 2016-10-20 2016-12-07 Almac Discovery Limited Pharmaceutical compounds
US11465983B2 (en) 2017-09-26 2022-10-11 Dana-Farber Cancer Institute, Inc. USP7 inhibitors for treating multiple myeloma
JP7508449B2 (ja) 2018-10-22 2024-07-01 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド Usp7の阻害

Similar Documents

Publication Publication Date Title
JP2023164918A5 (enExample)
JP2024520481A5 (enExample)
JP2009524691A5 (enExample)
JP2021522280A5 (enExample)
JP2017536395A5 (enExample)
JP2016503799A5 (enExample)
JP2019529444A5 (enExample)
JP2023553835A5 (enExample)
JP2018535967A5 (enExample)
JP2019529490A5 (enExample)
JP2019507130A5 (enExample)
JP2016500107A5 (ja) グルタミナーゼ阻害剤およびその使用方法
JP2017504651A5 (enExample)
JP2022503821A5 (enExample)
JP2015518899A5 (enExample)
JP2015051994A5 (enExample)
JP2009515988A5 (enExample)
JP2020506951A5 (enExample)
JP2017504650A5 (enExample)
JP2019500387A5 (enExample)
JP2016505586A5 (enExample)
JP2022529518A5 (enExample)
JP2012526728A5 (enExample)
JP2024539946A5 (enExample)
JP2014500265A5 (enExample)